mass spectrometry is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-08-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
| Property | Value | Notes |
|---|---|---|
| Typical form | Lyophilised powder | Reconstituted before use |
| Storage temperature, dry | -20 °C or below | Desiccated, protected from light |
| Purity determination | Reversed-phase HPLC | Reported as percentage of total peak area |
| Identity confirmation | Mass spectrometry | ESI or MALDI-TOF versus calculated mass |
| Common synonyms | Tβ4 fragment; thymosin beta-4 fragment | Naming varies between suppliers |
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
== History == Chlordiazepoxide (initially called methaminodiazepoxide) was the first benzodiazepine to be synthesized in the mid-1950s. The synthesis was derived from work on a class of dyes, quinazoline-3-oxides. It was discovered by accident when in 1957 tests revealed that the compound had hypnotic, anxiolytic, and muscle relaxant effects. "The story of the chemical development of Librium and Valium was told by Sternbach. The serendipity involved in the invention of this class of compounds was matched by the trials and errors of the pharmacologists in the discovery of the tranquilizing activity of the benzodiazepines. The discovery of Librium in 1957 was due largely to the dedicated work and observational ability of a gifted technician, Beryl Kappell. For some seven years she had been screening compounds by simple animal tests for muscle relaxant activity using Myanesin as a standard and then meprobamate and chlorpromazine when they became available. All compounds submitted by the chemical staff for central nervous activity were screened. It was this battery of tests that picked out RO 5-0690 (Librium, chlordiazepoxide) as being similar but more potent than meprobamate." Three years later chlordiazepoxide was marketed as a therapeutic benzodiazepine medication under the brand name Librium. Following chlordiazepoxide, in 1963 diazepam hit the market under the brand name Valium—and was followed by many further benzodiazepine compounds over the subsequent years and decades. In 1959 it was used by over 2,000 physicians and more than 20,000 patients.
U+039B Λ GREEK CAPITAL LETTER LAMDA (Λ) U+03BB λ GREEK SMALL LETTER LAMDA (λ) U+1D27 ᴧ GREEK LETTER SMALL CAPITAL LAMDA U+2C96 Ⲗ COPTIC CAPITAL LETTER LAULA U+2C97 ⲗ COPTIC SMALL LETTER LAULA U+A7DA LATIN CAPITAL LETTER LAMBDA U+A7DB LATIN SMALL LETTER LAMBDA U+1038D 𐎍 UGARITIC LETTER LAMDA U+1D6B2 𝚲 MATHEMATICAL BOLD CAPITAL LAMDA U+1D6CC 𝛌 MATHEMATICAL BOLD SMALL LAMDA U+1D6EC 𝛬 MATHEMATICAL ITALIC CAPITAL LAMDA U+1D706 𝜆 MATHEMATICAL ITALIC SMALL LAMDA U+1D726 𝜦 MATHEMATICAL BOLD ITALIC CAPITAL LAMDA U+1D740 𝝀 MATHEMATICAL BOLD ITALIC SMALL LAMDA U+1D760 𝝠 MATHEMATICAL SANS-SERIF BOLD CAPITAL LAMDA U+1D77A 𝝺 MATHEMATICAL SANS-SERIF BOLD SMALL LAMDA U+1D79A 𝞚 MATHEMATICAL SANS-SERIF BOLD ITALIC CAPITAL LAMDA U+1D7B4 𝞴 MATHEMATICAL SANS-SERIF BOLD ITALIC SMALL LAMDA
A composite mythological being with the body of a lion and the head of a human is present in the traditions, mythology and art of South and Southeast Asia. Variously known as puruṣamr̥ga (Sanskrit, "human-animal"), purushamirugam (Tamil, "human-animal"), naravirala (Sanskrit, "human-cat") in India, or as nara-simha (Sanskrit, "human-lion") in Sri Lanka, manussiha or manutthiha (Pali, "human-lion") in Myanmar, and norasingha (from Pali, "human-lion", a variation of the Sanskrit "nara-simha") or thep norasingha ("man-lion deity"), or nora nair in Thailand. Although, just like the "nara-simha", she/he has a head of a lion and the body of a human. In contrast to the sphinxes in Egypt, Mesopotamia, and Greece, of which the traditions largely have been lost due to the discontinuity of the civilization, the traditions related to the "Asian sphinxes" are very much alive today. The earliest artistic depictions of "sphinxes" from the South Asian subcontinent are to some extent influenced by Hellenistic art and writings. These hail from the period when Buddhist art underwent a phase of Hellenistic influence. Numerous sphinxes can be seen on the gateways of Bharhut stupa, dating to the 1st century B.C. In South India, the "sphinx" is known as puruṣamr̥ga (Sanskrit) or purushamirugam (Tamil), meaning "human-animal". It is found depicted in sculptural art in temples and palaces where it serves an apotropaic purpose, just as the "sphinxes" in other parts of the ancient world.
Mycoplasma pneumoniae Chlamydia pneumoniae Hepatitis B virus (HBV) Parvovirus B19 Adenovirus (ADV) Respiratory syncytial virus (RSV) The immune cell involvement in polymyalgia rheumatica includes the activation of dendritic cells and monocytes/macrophages, leading to inflammation in the synovium and bursae of the shoulder and hip girdles which is primarily mediated by the innate immune system. There is an altered balance between Th17 and Treg cells, with increased IL-6 levels driving Th17 cell activation. Disturbed B cell distribution and function are also observed, with a decrease in circulating B cells that recover after steroid treatment. Additionally, systemic activation of circulating monocytes is associated with increased IL-6 and IL-1 beta production. Associations of uncertain significance with multiple types of TNF have also been found. Despite the severe pain associated with the condition in multiple muscle groups, as well as the signs of systemic inflammation, muscle biopsies have found no signs of localized inflammation in muscle tissue in patients with PMR. Electromyography studies also typically turn up normal. The only locations known definitively to be inflamed in PMR are the synovial membranes and bursae of joints. Persons having the HLA-DR4 type of human leucocyte antigen appear to have a higher risk of PMR.
Sources: en.wikipedia.org
2,5-Dimethoxy-4-propylamphetamine (DOPR) is a psychedelic drug of the phenethylamine, amphetamine, and DOx families related to DOM. It is the derivative of DOM in which the methyl group at the 4 position has been replaced with a propyl group. The drug is taken orally. The drug acts as a serotonin receptor agonist, including of the serotonin 5-HT2A receptor. It produces psychedelic-like effects in animals. DOPR was first described in the literature by Alexander Shulgin in 1970. Subsequently, it was described in greater detail by Shulgin in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved).
f. antarctica (Vain.) Hue (1915) is now Polycauliona antarctica f. ectaneoides (Nyl.) Boistel (1903) is now Xanthoria ectaneoides f. ectaniza Boistel (1903) is now Rusavskia ectaniza f. polycarpa (Hoffm.) Arnold (1881) is now Polycauliona polycarpa subsp. calcicola (Oxner) Clauzade & Cl.Roux (1985) is now Xanthoria calcicola subsp. phlogina (Ach.) Sandst. (1912) is now Scythioria phlogina var. aureola (Ach.) Th.Fr. (1860) is now Xanthoria aureola var. australis Zahlbr. (1917) is now Jackelixia australis var. contortuplicata (Ach.) H.Olivier (1894) is now Xanthaptychia contortuplicata var. incavata (Stirt.) Js. Murray (1960) is now Dufourea incavata var. lobulata (Flörke) Rabenh. (1870) is now Seawardiella lobulata var. mandschurica Zahlbr. (1931) is now Zeroviella mandschurica var. rutilans (Ach.) Maheu & A.Gillet (1924) is now Xanthoria rutilans
When purity dropped, so did the number of people in rehab and people admitted to emergency rooms with methamphetamine in their systems. This reduction in purity was usually short-lived, however, as methamphetamine producers eventually found a way around the new regulations. Congress passed the Combat Methamphetamine Epidemic Act of 2005 (CMEA) as an amendment to the renewal of the USA Patriot Act. Signed into law by President George W. Bush on 6 March 2006, the act amended 21 U.S.C. § 830, concerning the sale of pseudoephedrine-containing products. The law mandated two phases, the first needing to be implemented by 8 April 2006, and the second to be completed by 30 September 2006. The first phase dealt primarily with implementing the new buying restrictions based on the amount, while the second phase encompassed the requirements of storage, employee training, and record keeping. Though the law was mainly directed at pseudoephedrine products it also applies to all over-the-counter products containing ephedrine, pseudoephedrine, and phenylpropanolamine, their salts, optical isomers, and salts of optical isomers. Pseudoephedrine was defined as a "scheduled listed chemical product" under 21 U.S.C. § 802(45(A)). The act included the following requirements for merchants ("regulated sellers") who sell such products:
BOP (benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate) is a reagent commonly used for the synthesis of amides from carboxylic acids and amines in peptide synthesis. It can be prepared from 1-hydroxybenzotriazole and a chlorophosphonium reagent under basic conditions. This reagent has advantages in peptide synthesis since it avoids side reactions like the dehydration of asparagine or glutamine residues. BOP has used for the synthesis of esters from the carboxylic acids and alcohols. BOP has also been used in the reduction of carboxylic acids to primary alcohols with sodium borohydride (NaBH4). Its use raises safety concerns since the carcinogenic compound HMPA is produced as a stoichiometric by-product. PyBOP, a related phosphonium reagent for amide bond formation PyAOP, a related phosphonium reagent for amide bond formation
In December 2010, 148 states supported a United Nations' General Assembly resolution calling for the states that use depleted uranium weapons in conflict to reveal where the weapons have been fired when asked to do so by the country upon whose territory they have been used. In April 2011, the Congress of Costa Rica passed a law prohibiting uranium weapons in its territories, becoming the second country in the world to do so. In December 2012, 155 states supported a United Nations' General Assembly resolution that recalled that, because of the ongoing uncertainties over the long-term environmental impacts of depleted uranium identified by the United Nations Environment Programme, states should adopt a precautionary approach to its use. In December 2014, 150 states supported a United Nations' General Assembly resolution encouraging states to provide assistance to states affected by the use of depleted uranium weapons, in particular in identifying and managing contaminated sites and material. In contrast to the previous biennial resolutions, Germany moved to an abstention from supporting to the resolutions. Prior to the vote, in a report to the United Nations Secretary General requested by 2012's resolution published in June 2014, Iraq had called for a global treaty ban on depleted uranium weapons.
Sources: en.wikipedia.org
Sealed, desiccated and protected from light, at -20 °C or lower for long-term storage. Short-term storage at refrigerator temperature is common in working laboratories.
Synthesis routes, purification steps and the analytical method used all affect the reported figure. A purity number is only comparable when the chromatographic conditions and detection wavelength are stated.
It reports what the supplier measured on a sample, which is useful but not absolute. Independent mass confirmation on the received lot is the more reliable check.
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.